IDEXX Laboratories (IDXX): Inside the Pet Diagnostics Leader’s 2025 Breakout 🚀
IDEXX Laboratories reported Q3 2025 revenue of $1.11 billion, up 13%, and EPS of $3.40, up 21%, beating expectations and raising full-year guidance. Shares have surged about 50–55% year-to-date, trading near all-time highs. The company holds nearly half the global veterinary diagnostics market and generates about 79% of sales from recurring revenue. Institutional ownership stands at approximately 94%.
